Caitong International Asset Management Co. Ltd Takes $6.41 Million Position in Eli Lilly and Company $LLY

Key Points

• Caitong International Asset Management initiated a $6.41 million position in Eli Lilly during the second quarter, purchasing 5,347 shares. Lilly represented 0.9% of Caitong’s portfolio, while institutional investors collectively owned 82.53% of the stock.
• Eli Lilly reported strong quarterly results, with earnings per share of $8.38 versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $35.50–$36.50.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $1,292.18, although Lilly’s elevated valuation, competition and pricing pressures remain risks. The company also declared a quarterly dividend of $1.73 per share, yielding approximately 0.6%.

Caitong International Asset Management Co. Ltd bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,347 shares of the company's stock, valued at approximately $6,413,000. Eli Lilly and Company comprises 0.9% of Caitong International Asset Management Co. Ltd's portfolio, making the stock its 22nd biggest position.

Several other hedge funds also recently added to or reduced their stakes in LLY. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company's stock valued at $38,002,744,000 after purchasing an additional 635,358 shares during the period. Morgan Stanley grew its stake in Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company's stock worth $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors grew its stake in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company's stock worth $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Eli Lilly and Company by 10.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company's stock worth $16,024,022,000 after purchasing an additional 1,432,069 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Up 0.4%

Eli Lilly and Company stock opened at $1,184.44 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market cap of $1.11 trillion, a P/E ratio of 39.75, a P/E/G ratio of 1.39 and a beta of 0.51. The business has a fifty day moving average of $1,171.52 and a two-hundred day moving average of $1,053.72. Eli Lilly and Company has a twelve month low of $685.15 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's revenue was up 47.7% compared to the same quarter last year. During the same period last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts forecast that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 23.22%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Barclays upped their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. Berenberg Bank raised their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a research note on Monday, June 22nd. Citigroup lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $1,292.18.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by insiders.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide results support higher guidance. Favorable trial results for retatrutide, Lilly’s next-generation obesity and diabetes candidate, reportedly prompted the company to lift its guidance. The update strengthens expectations that Lilly can extend its GLP-1 growth beyond Mounjaro and Zepbound. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: New OmniAb collaboration expands Lilly’s discovery pipeline. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program. The deal, which could provide OmniAb with up to $370 million in milestones, gives Lilly access to additional technology and potential future medicines while reinforcing its investment in pipeline development. OmniAb Announces Global Collaboration and License Agreement
• Positive Sentiment: Recent growth catalysts remain intact. Commentary highlights Lilly’s robust second-quarter performance, approximately 48% year-over-year revenue growth, UK regulatory approval, a Medicare access program and continuing GLP-1 demand. Analysts also point to strong momentum and a broad pipeline as reasons for long-term optimism. Eli Lilly’s Growth Story Keeps Adding Chapters
• Neutral Sentiment: Valuation remains debated. A discounted-cash-flow analysis suggests potential upside, but Lilly’s five-year total return of more than 360% and elevated trading multiples mean substantial future growth is already reflected in the stock. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?
• Negative Sentiment: Competition and pricing risks remain. Analysts view strong GLP-1 momentum favorably but caution that Lilly’s valuation is demanding and competition, pricing pressure and future patent headwinds could limit additional upside. LLY Up After Robust Q2 Results

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source